Use of artificial intelligence techniques for diagnosis of malignant pleural mesothelioma

Öz

Objective: Malignant pleural mesothelioma is a highly aggressive tumor of the serous membranes, which in humans results from exposure to asbestos and asbestiform fibers. The incidence of malignant mesothelioma is extremely high in some Turkish villages where there is a low-level environmental exposure to erionite, a fibrous zeolite. Therefore epidemiological studies are difficult to perform in Turkey. Methods: In this paper, a study on malignant pleural mesothelioma disease diagnosis was realized by using artificial immune system. Also, the artificial immune system result was compared with the result of the multi-layer neural network focusing on malignant pleural mesothelioma disease diagnosis and using same database. The malignant pleural mesothelioma disease dataset were prepared from a faculty of medicine’s database using patient’s hospital reports. Results: 97.74% accuracy performance is obtained by artificial immune system. The accuracy results of artificial immune system algorithm are much better than the accuracy results of multi-layer neural network algorithm. Conclusion: This system is capable of conducting the classification process with a good performance to help the expert while deciding the healthy and patient subjects. So, this structure can be helpful as learning based decision support system for contributing to the doctors in their diagnosis decisions. Key words: malignant pleural mesothelioma disease diagnosis, artificial immune system, machine learning based decision support system.

Anahtar Kelimeler

• malignant pleural mesothelioma disease diagnosis, artificial immune system, machine learning based decision support system

Use of artificial intelligence techniques for diagnosis of malignant pleural mesothelioma Malign plevral mezotelyoma tanısı için yapay zeka teknikleri kullanımı

Öz

Amaç: İnsanların beyin zarında bulunan, asbestos ve asbestiform liflerine maruz kalmakla oluşan kötü huylu plevral Mezotelyoma, oldukça saldırgan bir tümördür. Düşük seviyeli çevresel erionite fibrous zeolite’e maruz bırakılmış Türkiye’deki bazı kasabalarda Mezotelyoma görülme oranı oldukça yüksektir.Yöntemler: Bu çalışmada Mezotelyoma hastalığı teşhisi yapay bağışıklık sistemi kullanımı ile gerçekleştirilmiştir. Bununla beraber yapay bağışıklık sistemi sonuçları, aynı veri tabanını kullanan, Mezotelyoma hastalığının teşhisine odaklanmış çok katmanlı yapay sinir ağı sonuçları ile karşılaştırılmıştır. Mezotelyoma hastalığı veri seti, hastaların hastane raporlarını kullanan tıp fakültesi veri tabanından alınmıştır.Bulgular: Yapay bağışıklık sistemi tarafından hastalık teşhisi için %97,74 doğruluk oranında bir performans elde edilmiştir. Yapay bağışıklık sistemi algoritmasının doğruluk sonuçları çok katmanlı yapay sinir ağı algoritmasından çok daha iyi olduğu görülmüştür.Sonuç: Bu sistem uzmana, sağlıklı ve hasta kişiyi sınıflandırma sürecinde doğru teşhisi bulma yönünde iyi bir performans sağlar. Böylece bu yapı ile doğru teşhis sonucuna ulaşmada doktorlara bir karar destek sistemi olarak yardımcı olur

Anahtar Kelimeler

• Kötü huylu plevral mezotelyoma hastalığının teşhisi, yapay bağışıklık sistemi, makine öğrenme tabanlı karar destek sistemi

Kaynakça

1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma
2. and asbestos exposure in the North Western Cape
3. Povince. Br J Indust Med 1960;17:266-271.
4. Emri S, Akbulut H, Zorlu F, et al. Prognostic significance of
5. flow cytometric DNA analysis in patients with malignant
6. pleural mesothelioma. Lung Cancer 2001; 33:109-114.
7. Barış B, Demir AU, Shehu V, et al. Environmental fibrous
8. zeolite (erionite) exposure and malignant tumors other

9. than mesothelioma. J Environ Pathol Toxicol Oncol 1996;
10. :183-189.
11. Dumortier P, Çöplü L, De Maertelaer V, et al. Assessment of
12. environmental asbestos exposure in Turkey by bronchoalveolar
13. lavage. Am J Respir Crit Care Med 1998; 158:1815-
14. -
15. Selcuk ZT, Coplu L, Emri S, et al. Malignant pleural mesothelioma
16. due to environmental mineral fiber exposure in
17. Turkey. Analysis of 135 cases. Chest 1992;102:790-796.
18. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma
19. epidemic Brit J Cancer 1999;79:666-672.
20. Burgers JA, Damhuis RAM, Prognostic factors in malignant
21. mesothelioma Lung Cancer 2004;56:123-129.
22. Zervos MD, Bizekis C. Pass HI: Malignant mesothelioma
23. Curr Opin Pulm Med 2008, 14:303-309.
24. National Mesothelioma committee, http://www.mesothelioma-tr.org/
25. (last accepted: 10 November 2014)
26. Tanrikulu AC, Senyigit A, Dagli CE, et al. Environmental
27. malignant pleural mesothelioma in Southeast Turkey. Saudi
28. Med J 2006;27:1605-1607.
29. Senyiğit A, Bayram H, Babayiğit C, et al. Malignant pleural
30. mesothelioma caused by environmental exposure to asbestos
31. in the Southeast of Turkey: CT findings in 117 patients.
32. Respiration 2000;67:615-622.
33. Senyiğit A, Babayiğit C, Gökirmak M, et al. Incidence of
34. malignant pleural mesothelioma due to environmental asbestos
35. fiber exposure in the southeast of Turkey. Respiration
36. ;67:610-614.
37. Can N, Puyan FÖ, Öz F, et al. Warthin-like papillary thyroid
38. carcinoma: A rare tumor of the thyroid. Dicle Medical Journal
39. ;38 :482-485.
40. Alberts AS, Faikson G, Goedhals L, et al. Malignant pleural
41. mesothelioma: a disease unaffected by current therapeutic
42. maneuvers. J. Clin Oncol 1988;6:527-535.
43. Vogelzang NJ. Malignant mesothelioma: diagnostic and
44. management strategies for 1992. Semin Oncol 1992;19:64-
45. -
46. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors
47. in diffuse malignant pleural mesothelioma. Chest
48. ;93:159-162.
49. Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic
50. value of the serum tumour markers Cyfra 21-1 and tissue
51. polypeptide antigen in malignant mesothelioma. Lung Cancer
52. ;25:25-32.
53. Sugarbaker D.J., Jaklitseh M.T., Liptay M.J., Mesothelioma
54. and radical multimodality therapy: who benefits? Chest
55. ; 107(Suppl.): 3455-3505.
56. Sugarbaker D.J., Norberto J.J., Multimodality management
57. of malignant pleural mesothelioma. Chest 1998; 113 (Suppl.):
58. -655.
59. Metintas M, Metintas S, Ucgun I, et al. Prognostic factors in
60. diffuse malignant pleural mesothelioma: pretreatment clinical
61. and laboratory characteristics. Resp. Medicine 2001:
62. :829-835.
63. O. Er, et al. Artificial intelligence techniques for diagnosis of malignant pleural mesothelioma 11
64. Dicle Tıp Derg / Dicle Med J www.diclemedj.org Cilt / Vol 42, No 1, 5-11
65. Edwards JG, Abrams KR, Leverment JN. Prognostic factors
66. for malignant mesothelioma in 142 patients: validation of
67. CALGB and EORTC prognostic scoring systems. Thorax
68. ;55:731-735.
69. Curran D, Sahmoud T, Therasse P. Prognostic factors
70. in patients with pleural mesothelioma: the European
71. Organisa¬tion for research and treatment of cancer experience.
72. J Clin OncoI 1998;16:145-152.
73. Montanaro F, Rosato R, Gangemi M, et al. Survival of pleural
74. malignant mesothelioma in Italy: a population-based
75. study. Int J Cancer. 2009;124:194-200.
76. Kadoz H, Ozsen S, Arslan A and Gunes S. Medical application
77. of information gain based artificial immune recognition
78. system (AIRS): Diagnosis of thyroid disease. Expert
79. System with Application. 2008;36:3086-3092.
80. Engin O, Döyen A. Artificial Immune Systems and Applications
81. in Industrial Problems. GU J Sci 2004;17:71-84.
82. Dasgupta D. Advances in Artificial Immune Systems. EEE
83. Computational Intelligence Magazine, University of Memphis,
84. USA, November 2006; 40-49.
85. Kayaer K, Yıldırım T. Medical Diagnosis on Pima Indian
86. Diabetes Using General Regression Neural Networks. In
87. Proc. of International Conference on Artificial Neural Networks
88. and Neural Information Processing (ICANN/ICONIP),
89. Istanbul, 2003; 181-184.
90. Delen D, Walker G, Kadam A., Predicting breast cancer
91. survivability: A comparison of three data mining methods,
92. Artificial Intelligence in Medicine Artificial Intelligence in
93. Medicine, 2005; 34: 113–127.
94. Temurtas F. A comparative study on thyroid disease diagnosis
95. using neural networks. Expert Systems with Applications,
96. ; 36: 944-949.
97. Rumelhart DE, Hinton GE, Williams RJ. Learning internal
98. representations by error propagation, in D.E. Rumelhart,
99. J.L. McClelland (Eds.), Parallel Distributed Processing:
100. Explorations in the Microstructure of Cognition, 1986; 1:
101. –362.
102. Brent RP. Fast training algorithms for multi-layer neural
103. nets. IEEE Trans. Neural Networks, 1991; 2: 346–354.
104. Gori M, Tesi A. On the problem of local minima in backpropagation.
105. IEEE Trans. Pattern Anal. Machine Intell.
106. ; 14: 76–85.
107. Hagan MT, Menhaj M. Training feed forward networks
108. with the Marquardt algorithm. IEEE Trans. Neural Networks,
109. ; 5: 989-993.
110. Hagan MT, Demuth HB, Beale MH. Neural Network Design.
111. PWS Publishing, Boston, MA, 1996.
112. Gulbag A, Temurtas F. A study on quantitative classification
113. of binary gas mixture using neural networks and adaptive
114. neuro fuzzy inference systems. Sensor Actuators B, 2006;
115. : 252-262.
116. Trojanowski K, Wierzchon ST. Searching for Memory in
117. Artificial Immune System. The Eleventh International
118. Symposium on Intelligent Information Systems, June 3-6,
119. -
120. De Castro LN and Timmis J. A Novel approach to pattern
121. recognition. Artificial Neural Networks in pattern Recognition,
122. University of Paisley: 2002; 67-84.
123. De Castro LN and Von Zuben FJ. The clonal selection algorithm
124. with engineering applications. GECCO 2000, Las
125. Vegas, Nevada, USA, July 8, 2000.
126. Er O, Sertkaya C, Temurtas F and Tanrikulu AC. A Comparative
127. study on chronic obstructive pulmonary and pneumonia
128. diseases diagnosis using neural networks and artificial
129. immune system. Journal of Medical Systems, 2009;
130. : 485-492.
131. Watkins A. AIRS: A resource limited artificial immune classifier.
132. Master Thesis, Mississippi State University, 2001.
133. Sertkaya C. Immune Base System in Computer Security,
134. Master Thesis. Sakarya University. Institute of Science and
135. Technology, 2009.
136. Er O, Yumusak N, Temurtas F. Chest diseases diagnosis using
137. artificial neural networks. Expert Systems with Applications,
138. ; 37: 7648-7655.
139. Ozyılmaz L, Yıldırım T. Diagnosis of thyroid disease using
140. artificial neural network methods. In Proc. of ICONIP’02
141. th international conference on neural information processing,
142. Orchid Country Club, Singapore, 2002; 2033–2036.
143. Er O, Temurtas F. A study on chronic obstructive pulmonary
144. disease diagnosis using multilayer neural networks. Journal
145. of Medical Systems, 2008; 32: 429-432.
146. Er O, Temurtas F, Tanrikulu AC. Tuberculosis disease diagnosis
147. using artificial neural networks. J Med Systems
148. ;34:299-302.
149. Er O, Tanrikulu AC, Abakay A, Temurtas F. An approach
150. based on probabilistic neural network for diagnosis of Mesothelioma’s
151. disease. Computers & Electrical Engineering
152. ;38:75-81.